Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

WuXi STA expands peptide manufacturing capacity to meet global demand

By Brian Buntz | April 19, 2023

Changzhou Birdview

[Image courtesy of WuXi STA]

WuXi STA, a prominent global contract research, development and manufacturing organization (CRDMO), has increased its peptide manufacturing output at its Changzhou campus. Located in southern Jiangsu province in China, Changzhou is part of the Yangtze River Delta region, which is among the most economically developed areas in the country.

WuXi STA’s expansion includes two additional 2,000 L reactors and a large-scale continuous purification system. This expansion enables WuXi STA to provide immediate access to capacity, reducing wait times and accelerating project timelines for clients.

WuXi STA peptide manufacturing capacity promises to cut turnover time

The WuXi subsidiary says the new purification system will reduce turnover time and minimize solvent consumption, making the peptide and oligonucleotide manufacturing process more efficient and sustainable. The company’s WuXi TIDES platform is non-therapeutic-specific and will support any type of oligonucleotides, peptides and their conjugates.

The company says the platform is particularly well suited for TIDES projects in rare diseases involving accelerated pathways for drug targets. WuXi uses the term “TIDES” to refer to a group of drugs that include oligonucleotides, peptides and related synthetic conjugates, which are the focus of its platform’s drug development efforts.

WuXi STA’s increased capacity and enhanced capabilities in its Changzhou campus will help it meet the global demand for suitable CDMO partners and drive rapid growth among both new and existing customers. The company underscores that it can quickly move projects from discovery to commercialization, contributing to more rapid initial stages of discovery and development.

Peptides’ potential

Peptides not only serve as a modality in themselves, but they can also work in conjunction with small molecules, such as Peptide Drug Conjugates (PDC). The manufacturing of therapeutic PDCs requires different chemistry efforts, including unnatural amino acids, toxins, linkers, ligands and peptides. WuXi TIDES’ end-to-end offering reduces time significantly by housing all required sites for various chemistry modifications in close proximity.

WuXi TIDES plans to significantly expand its footprint in the coming years. A new Taixing site in Jiangsu will have both oligo and peptide capabilities operational by next year. Additionally, a new 50-acre API process R&D and manufacturing site in Singapore is under development, with Phase I, including a large-scale manufacturing plant for oligonucleotides, peptides, and related synthetic conjugates, expected to begin operation in 2026. Another facility in Middletown, Delaware in the U.S., is also under development. Phase I of construction will focus on preparing the facility for formulation development and manufacturing, including packaging, labeling and distribution for oral and parenteral drug products. WuXi STA expects the site to begin operation in 2026.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE